MYND Life Sciences Inc. Granted Management Cease Trade Order

Vancouver, British Columbia--(Newsfile Corp. - March 1, 2023) - MYND Life Sciences Inc. (CSE: MYND) ("MYND" or the "Company") announces that it has been advised by its external auditors (the "Auditors") that they will not be in a position to complete their work on the Company's annual consolidated financial statements for the year ended October 31, 2022 (the "2022 Financial Statements") prior to the filing deadline of February 28, 2023 (the "Annual Filing Deadline"). As a result, the Company will not be able to file the 2022 Financial Statements, accompanying Management Discussion & Analysis and CEO and CFO certifications, and the Annual Information Form (collectively, the "2022 Annual Filings") prior to the Annual Filing Deadline as required under applicable Canadian securities laws. The Company anticipates filing the 2022 Financial Statements by March 31, 2023.

The Company further announces that it has been granted a management cease trade order (MCTO) under National Policy 12-203 of the Canadian Securities Administrators ("NP 12-203") imposed against certain insiders of the Company. The MCTO will remain in effect until the Company has filed its audited statements and the Executive Director of the BCSC has revoked the order. The Company will be required to comply with the provisions of the alternative information guidelines as set out in NP 12-203 for so long as the MCTO remains in effect, including the issuance of bi-weekly default status reports by way of press releases.

The Company will make further announcements with respect to the status of the 2022 Annual Filings as and when appropriate.

ABOUT MYND LIFE SCIENCES INC.

MYND Life Sciences Inc. is a medical biotech drug research and development company focused on neuro-pharmaceutical and novel drug development, diagnostics and vaccines. MYND is developing new biological entities (NBEs) and new chemical entities (NCEs) and differentiates itself from other (bio)pharmaceutical companies by unique molecular concepts for overcoming disease. The Company advances pharmaceutical developments through rigorous science and clinical trials while diligently patenting and safeguarding its intellectual property.

Contact:
Dr. Lyle Oberg, MD, CEO
Email: [email protected]
Phone: 780 965-0122
Web: www.myndsciences.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/156859

You May Also Be Interested In

• Richards Group Inc. Announces Change of Auditor
• HII’s Newport News Shipbuilding Completes Successful Acceptance Sea Trials of John F. Kennedy (CVN 79)
• Dogecoin Price Prediction: $0.15 Bull Case Would More Than Double DOGE as AlphaPepe $1 Roadmap Talk Targets Bigger Upside